| Recruiting | A Study of Lorigerlimab in Participants With Advanced Solid Tumors Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma | Phase 2 | 2025-05-01 |
| Recruiting | A Study of MGC028 in Participants With Advanced Solid Tumors Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma | Phase 1 | 2025-02-13 |
| Recruiting | A Study of MGC026 in Participants With Advanced Solid Tumors Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer | Phase 1 | 2024-03-06 |
| Completed | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent | Phase 2 | 2023-09-28 |
| Terminated | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer | Phase 2 | 2023-06-13 |
| Completed | A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1 | Phase 1 | 2022-09-26 |
| Recruiting | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma | Phase 1 | 2022-07-13 |
| Completed | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma | Phase 1 | 2022-04-19 |
| Terminated | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma | Phase 2 | 2021-03-17 |
| Withdrawn | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | Phase 2 / Phase 3 | 2019-10-01 |
| Completed | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Can Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer | Phase 2 / Phase 3 | 2019-09-30 |
| Completed | MGD019 DART® Protein in Unresectable/Metastatic Cancer Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma | Phase 1 | 2018-12-12 |
| Terminated | MGC018 With or Without MGA012 in Advanced Solid Tumors Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma | Phase 1 / Phase 2 | 2018-11-21 |
| Completed | MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy HIV-1-infection | Phase 1 | 2018-09-25 |
| Completed | MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer Colorectal Cancer Metastatic | Phase 1 / Phase 2 | 2018-06-04 |
| Completed | MGD009/MGA012 Combination in Relapsed/Refractory Cancer Advanced Solid Tumors | Phase 1 | 2018-02-27 |
| Completed | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer | Phase 1 | 2017-08-18 |
| Completed | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma | Phase 1 | 2016-12-01 |
| Completed | Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Juncti Gastric Cancer, Stomach Cancer, Esophageal Cancer | Phase 1 / Phase 2 | 2016-01-01 |
| Terminated | Safety Study of MGD009 in B7-H3-expressing Tumors Mesothelioma, Bladder Cancer, Melanoma | Phase 1 | 2015-09-01 |
| Completed | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Ca HER-2 Positive Breast Cancer, Metastatic Neoplasm | Phase 3 | 2015-08-24 |
| Completed | Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer | Phase 1 | 2015-07-01 |
| Completed | Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer Melanoma, Non Small Cell Lung Cancer | Phase 1 | 2015-03-26 |
| Completed | Phase 1 Study of MGD010 in Healthy Subjects Healthy Subjects | Phase 1 | 2015-02-01 |
| Completed | Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma Colorectal Carcinoma | Phase 1 | 2014-10-01 |
| Terminated | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) AML | Phase 1 / Phase 2 | 2014-06-09 |
| Terminated | Tissue Procurement Substudy for Participants in Study CP-MGA271-01 Melanoma | Phase 1 | 2013-07-01 |
| Completed | Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advance Breast Cancer | Phase 2 | 2013-03-01 |
| Completed | Safety Study of MGA271 in Refractory Cancer Prostate Cancer, Melanoma, Renal Cell Carcinoma | Phase 1 | 2011-07-01 |
| Terminated | Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes Type 1 Diabetes Mellitus | Phase 1 | 2010-08-01 |
| Completed | Safety Study of MGAH22 in HER2-positive Carcinomas Breast Cancer, Gastric Cancer | Phase 1 | 2010-07-01 |
| Terminated | Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis Psoriasis | Phase 1 / Phase 2 | 2009-12-01 |
| Terminated | Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Di Type 1 Diabetes Mellitus | Phase 3 | 2009-09-01 |
| Terminated | Treatment of West Nile Virus With MGAWN1 West Nile Neuroinvasive Disease, West Nile Virus Infection, Encephalitis | Phase 2 | 2009-05-01 |
| Terminated | Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01 Type 1 Diabetes Mellitus | N/A | 2009-02-01 |
| Terminated | Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer Pancreatic Cancer | Phase 2 | 2008-04-15 |
| Completed | A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults West Nile Virus | Phase 1 | 2007-08-01 |
| Completed | The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus | Phase 2 / Phase 3 | 2006-10-01 |
| Completed | RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Cancer | Phase 1 | 2004-12-01 |
| No Longer Available | Flotetuzumab Expanded Access Program Acute Myeloid Leukemia, AML, AML, Adult Recurrent | — | — |
| No Longer Available | Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Viru West Nile Virus Infection | — | — |